Companies › Bridge Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BBT-207 EGFR inhibitor | – | Phase 1 | EGFR Mutant Advanced Non-Small Cell Lung Cancer | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05920135 | BBT-207 | Phase 1 | EGFR Mutant Advanced Non-Small Cell Lung Cancer | Oncology | Aug 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.